Histopathologic and Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations
Authors' conclusion
Bethesda III-VI thyroid nodules with isolated RAS mutations have a low rate of aggressive histopathologic features and are unlikely to recur. Thyroid lobectomy may be sufficient treatment for these tumors.
Study context
- Population
- Patients with Bethesda III–VI thyroid nodules with molecular testing (ThyroSeq v3), single institution, 2016–2021
- Participants
- 368 consecutive patients
- Exposure
- Isolated RAS-mutated vs isolated BRAF V600E-mutated nodules
- Isolated RASn = 50
- Isolated BRAFn = 86reference
- Outcome
- Malignancy rate on final pathology
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
| Group | Value | NIFTP | Benign histopathology |
|---|---|---|---|
| Isolated RAS | 46% | 32% | 22% |
| Isolated BRAF | 100% |
Value
Isolated RAS46%
Isolated BRAF100%
NIFTP
Isolated RAS32%
Isolated BRAF— not stated in the abstract
Benign histopathology
Isolated RAS22%
Isolated BRAF— not stated in the abstract
Observational data: associations, not effects.
Further findings
Lymph node metastasis (RAS: among malignant histopathology)
P = 0.016
| Outcome | Isolated RAS | Isolated BRAF |
|---|---|---|
| Structural recurrence · median follow-up 5 years | 0 events | 6% |
Original publication
Histopathologic and Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations. Endocr Pract. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →